Drug · DIN 02432072
GABAPENTIN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 19, 2023; first marketed May 19, 2023.
- Drug Identification Number (DIN)
- 02432072
- Company (DIN owner)
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Gabapentin N02BF01
- Class
- Human
- Record last updated
- November 10, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| GABAPENTIN | 600 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 29, 2021: NOC 26939Abbreviated New Drug Submission (ANDS) · Administrative: Change in Product Ownership
- March 24, 2017: NOC 19093Supplement to an Abbreviated New Drug Submission (SANDS) · New dosage form
Other DINs named GABAPENTIN
- DIN 02246314 · Marketed
- DIN 02246315 · Marketed
- DIN 02246316 · Marketed
- DIN 02353245 · Marketed
- DIN 02353253 · Marketed
- DIN 02353261 · Marketed
- DIN 02388200 · Marketed
- DIN 02388219 · Marketed
- DIN 02431289 · Marketed
- DIN 02432080 · Marketed
- DIN 02238671 · Cancelled Pre Market
- DIN 02238672 · Cancelled Pre Market
- DIN 02238673 · Cancelled Pre Market
- DIN 02273853 · Cancelled Post Market
- DIN 02304775 · Cancelled Post Market
- DIN 02304783 · Cancelled Post Market
- DIN 02304791 · Cancelled Post Market
- DIN 02342650 · Cancelled Pre Market
- DIN 02342669 · Cancelled Pre Market
- DIN 02342677 · Cancelled Pre Market